Macromoltek logo

Macromoltek

Computational antibody design

Winter 2018Healthcare / Healthcare -> Drug Discovery and DeliveryAustin, TX, USA14 employees
AI-powered Drug Discovery
Deep Learning
Therapeutics

About

Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.

Founders (2)

Monica Berrondo
Founder/CEO
Susana Kaufmann
Founder/CTO

Details

Status
Active
Stage
Early
Team Size
14
Regions
United States of America, America / Canada